|
 |
|
LETTER TO THE EDITOR |
|
|
|
| Year : 2011 | Volume
: 16
| Issue : 4 | Page : 173-174 |
| |
Role of propranolol in hemangiomas
Vishal Gajbhiye, Sasanka Nath, Souvik Chatterjee, Avidip De, Dipak Ghosh, Sukanta Kumar Das
Department of Pediatric Surgery, Medical College and Hospital, Kolkata, West Bengal, India
| Date of Web Publication | 31-Oct-2011 |
Correspondence Address:
Vishal Gajbhiye
136, Sarat Bose Road, Kolkata - 700 029, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-9261.86892
How to cite this article:
Gajbhiye V, Nath S, Chatterjee S, De A, Ghosh D, Das SK. Role of propranolol in hemangiomas. J Indian Assoc Pediatr Surg 2011;16:173-4 |
How to cite this URL:
Gajbhiye V, Nath S, Chatterjee S, De A, Ghosh D, Das SK. Role of propranolol in hemangiomas. J Indian Assoc Pediatr Surg [serial online] 2011 [cited 2023 Jun 1];16:173-4. Available from: https://www.jiaps.com/text.asp?2011/16/4/173/86892 |
Sir,
Hemangiomas of infancy are common, benign, self-limiting malformations, but a significant percent of these lesions are associated with substantial morbidity and cosmetic disfigurement in infancy and childhood. [1] Current treatment options for problematic hemangiomas include systemic or intralesional corticosteroids, chemotherapeutic agents (vincristine, alfa-interferon), laser, surgery or a combination of these therapies. Unfortunately, each treatment option has limited therapeutic benefit, with its own side-effect and risks. Few case reports have been published where hemangiomas regress rapidly when treated with propranolol at a dose of 2 mg/kg/day. [2],[3]
Propranolol is a nonselective beta-blocker. Its vasoconstrictive property results in reduction in color and size of the hemangioma. Its primary effect, however, appears to be alteration in the progression of angiogenesis in the hemangioma, by decrease in expression of bFGF and VEGF. In addition, propranolol may promote involution of hemangiomas by triggering apoptosis in endothelial cells. [2]
We have performed this prospective study to explore the impact of propranolol on hemangiomas at our center. A total of 40 patients from 3 weeks to 12 months of age with 21 girls and 19 boys were taken in this study. The study period was from February 2010 to July 2011. Detailed clinical examination with history of previous treatment with steroid or other medication was taken. Contraindications for propranolol (e.g., bronchial asthma, hypoglycemia, gastroesophageal reflux, etc.) were recorded and such children were excluded from the study.
An oral dose of 2 mg/kg/day divided into two to three doses was given to each child. [2] Serial photographs were taken at 3-4 weeks intervals during the course of their therapy to record clinical response. The doses were adjusted as the child grows by taking regular body weight of the child. Propranolol was weaned at the end of treatment by reducing the dose to one-half for 1-2 weeks, and then stopped.
Ten of the 40 patients (25%) had complete resolution with no residual disease. Average time taken was 4 months for complete resolution in these cases. Twenty-nine patients (72.5%) showed progressive reduction in size and color of their hemangiomas [Figure 1]. These patients were considered to be partial responders and are on further propranolol therapy. Only one patient (2.5%) had persistent hemangioma growth despite propranolol therapy for 4 months, and was termed nonresponder. In this study, it is also observed that lesions that respond to therapy earlier show complete resolution earlier. There were no report of any side-effects during the study. | Figure 1: (a) Photograph at onset of treatment. (b) Four months posttreatment photograph showing almost complete response
Click here to view |
Based on the successful results of our study and few other case reports, propranolol appears to be a valuable and effective treatment option for hemangiomas at therapeutic doses (2 mg/kg/day), and it may revolutionize the treatment of hemangiomas.
 References | |  |
| 1. | Kilcline C, Frieden IJ. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol 2008;25:168-73. 
[PUBMED] [FULLTEXT] |
| 2. | Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
|
| 3. | Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: Case report of novel treatment. Laryngoscope 2009;119:2051-4.
[PUBMED] [FULLTEXT] |
[Figure 1]
| This article has been cited by | | 1 |
Interventions for infantile haemangiomas of the skin |
|
| Monica Novoa, Eulalia Baselga, Sandra Beltran, Lucia Giraldo, Ali Shahbaz, Hector Pardo-Hernandez, Ingrid Arevalo-Rodriguez | | Cochrane Database of Systematic Reviews. 2018; 2018(4) | | [Pubmed] | [DOI] | | | 2 |
Propranolol and Infantile Hemangiomas Four Years Later: A Systematic Review |
|
| Ann L. Marqueling,Vikash Oza,Ilona J. Frieden,Katherine B. Puttgen | | Pediatric Dermatology. 2013; 30(2): 182 | | [Pubmed] | [DOI] | | | 3 |
Propranolol and infantile hemangiomas four years later: A systematic review |
|
| Marqueling, A.L. and Oza, V. and Frieden, I.J. and Puttgen, K.B. | | Pediatric Dermatology. 2013; 30(2): 182-191 | | [Pubmed] | |
|
|
|
|
